Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Tirzepatide (Zepbound) and semaglutide (Wegovy) are both medications used to help with weight loss and belong to the class of glucagon-like peptide-1 (GLP-1) receptor agonists. However, they have some differences. Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, while semaglutide is solely a GLP-1 receptor agonist. Tirzepatide is also approved to treat moderate-to-severe sleep apnea, whereas semaglutide is approved to lower the risk of heart attack, stroke, and death due to heart problems in adults with heart disease. Both medications are injected under the skin once a week, but their dosing schedules differ. Tirzepatide starts at 2.5 mg and can go up to 15 mg, while semaglutide starts at 0.25 mg and can go up to 2.4 mg. Common side effects for both include nausea, diarrhea, and stomach pain. Both medications have potential interactions with other medications, such as diabetes medications, warfarin (Jantoven, Coumadin), and birth controll pills. Both are not recommended for people with a history of certain thyroid cancers.
Zepbound (tirzepatide)
Wegovy (semaglutide)
Zepbound (tirzepatide)
Wegovy (semaglutide)
Summary of Zepbound vs. Wegovy
Summary for GIP and GLP-1 agonist
Prescription only
Zepbound (tirzepatide) is an injectable medication that's used along with diet and exercise. It helps with weight loss in adults who meet criteria for weight management therapy. It's also approved to treat moderate-to-severe sleep apnea. This medication belongs to the drug class called GIP and GLP-1 agonists. The dosage is 1 injection under the skin once a week. Common side effects include nausea, diarrhea, and injection site reactions. Zepbound (tirzepatide) is only available as a brand-name medication.
Summary for GLP-1 agonist
Prescription only
Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It's an injection that's given under the skin. The medication is used along with a lower-calorie diet and regular exercise. Wegovy (semaglutide) is approved to help with weight loss in certain adults and children 12 years and over. It also helps lower the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease. And, it's also approved for certain adults with a liver problem called metabolic dysfunction-associated steatohepatitis (MASH). The dosing schedule is an injection once a week. Common side effects are nausea, diarrhea, and stomach pain.